Betta Pharmaceuticals Co., Ltd.
Records under this name other than the patents Betta Pharmaceuticals Co., Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 11 patents it holds.
Showing 1 to 10 of 10 · Back to Betta Pharmaceuticals Co., Ltd.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,275,737 | Polymorphs of a Kinase Inhibitor, Pharmaceutical Compositions Containing Such a Compound, Preparation Methods, and Applications Formerly held In force · High confidence | In force | High confidence | |
| US 11,365,196 | FGFR inhibitor and application thereof Lapsed on the fee record Ended Jun 21, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jun 21, 2026 | From the USPTO record |
| US 8,742,138 | Compounds as hypoxia mimetics, and compositions and uses thereof Formerly held Lapsed on the fee record Ended Jun 3, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jun 3, 2026 | From the USPTO record |
| US 9,688,687 | Polymorphic forms of icotinib phosphate and uses thereof Lapsed on the fee record Ended Jun 27, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jun 27, 2025 | From the USPTO record |
| US 9,617,257 | Fused pyridine derivatives useful as c-Met tyrosine kinase inhibitors Lapsed on the fee record Ended Apr 11, 2025 · From the USPTO record | Lapsed on the fee record | Ended Apr 11, 2025 | From the USPTO record |
| US 9,487,570 | Glucagon like peptide analogs, composition, and method of use Lapsed on the fee record Ended Nov 8, 2024 · From the USPTO record | Lapsed on the fee record | Ended Nov 8, 2024 | From the USPTO record |
| US 10,577,364 | Crystalline form of fused pyridine derivative's maleate and uses thereof Lapsed on the fee record Ended Mar 3, 2024 · From the USPTO record | Lapsed on the fee record | Ended Mar 3, 2024 | From the USPTO record |
| US 9,242,991 | Substituted fused heterocycles as c-Met tyrosine kinase inhibitors Lapsed on the fee record Ended Jan 26, 2024 · From the USPTO record | Lapsed on the fee record | Ended Jan 26, 2024 | From the USPTO record |
| US 10,059,688 | Protein tyrosine kinase modulators and methods of use Lapsed on the fee record Ended Aug 28, 2022 · From the USPTO record | Lapsed on the fee record | Ended Aug 28, 2022 | From the USPTO record |
| US 9,783,524 | Protein tyrosine kinase modulators and methods of use Lapsed on the fee record Ended Oct 10, 2021 · From the USPTO record | Lapsed on the fee record | Ended Oct 10, 2021 | From the USPTO record |